Literature DB >> 18801145

Quality of psoriasis care in Germany--results of the national study PsoHealth 2007.

Matthias Augustin1, Kristian Reich, Christine Reich, Sandra Purwins, Stephan Jeff Rustenbach, Ines Schäfer, Marc Radtke.   

Abstract

BACKGROUND: Many different forms of treatment are available for psoriasis. The German standard is the national AWMF S3 guideline. A national survey on psoriasis care in 2005 indicated deficits in psoriasis care in Germany. AIM: Assessment of the health care situation of patients with psoriasis in Germany.
METHODS: Nation-wide cross-sectional study, in 142 dermatological practices and clinics. The following data were documented: a) Doctor Questionnaire: Treatment, illnesses, clinical characteristics and severity (PASI). b) Patient Questionnaire: Quality of life (QoL), patient relevant therapeutic benefits and satisfaction with the quality of the care. A panel of experts developed and analyzed 8 criteria as indicators of the quality of care.
RESULTS: Of the 2009 evaluated patients, 11.6% suffered from severe psoriasis (PASI > 20) and 27.4% from moderate psoriasis (PASI 10-20). The average PASI value was 10.1, and the DLQI 7.5. 32.2% of patients had a serious reduction in their QoL (DLQI > 10). The share of patients with preceding systemic therapy was 47.3%, in severe psoriasis 62.1%, while 20.1% of the patients had received inpatient treatment. The average number of days absent from work was 3.4. Compared to 2005, all 8 indicators improved.
CONCLUSION: Significant numbers of psoriasis patients show serious quality of life reductions and high grades of clinical severity. In comparison to 2005, there has been a notable, nation-wide improvement in psoriasis care.

Entities:  

Mesh:

Year:  2008        PMID: 18801145     DOI: 10.1111/j.1610-0387.2008.06807.x

Source DB:  PubMed          Journal:  J Dtsch Dermatol Ges        ISSN: 1610-0379            Impact factor:   5.584


  9 in total

Review 1.  [Calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis. A review].

Authors:  M A Radtke; K Herberger; T Kornek; M Augustin
Journal:  Hautarzt       Date:  2010-09       Impact factor: 0.751

Review 2.  [Health services research in dermatology. Current status].

Authors:  N Franzke; M Augustin
Journal:  Hautarzt       Date:  2011-03       Impact factor: 0.751

Review 3.  [Improved quality of healthcare through dermatological health services research : Effects of structured programs on psoriasis and skin cancer].

Authors:  M Gehoff; M Augustin
Journal:  Hautarzt       Date:  2018-10       Impact factor: 0.751

4.  [Modern therapy of psoriasis : evidence-based, patient-centered, goal-oriented].

Authors:  W-H Boehncke
Journal:  Hautarzt       Date:  2012-07       Impact factor: 0.751

5.  Predictors of biologic treatment of psoriasis: a non-interventional study.

Authors:  Luis Puig; Tao Fan; Qian Ding; Nancy E Smith
Journal:  Clinicoecon Outcomes Res       Date:  2014-02-17

6.  Sex-related impairment and patient needs/benefits in anogenital psoriasis: Difficult-to-communicate topics and their impact on patient-centred care.

Authors:  Neuza da Silva; Matthias Augustin; Anna Langenbruch; Ulrich Mrowietz; Kristian Reich; Diamant Thaçi; Wolf-Henning Boehncke; Natalia Kirsten; Alexandra Danckworth; Rachel Sommer
Journal:  PLoS One       Date:  2020-07-01       Impact factor: 3.240

7.  Nail psoriasis as a severity indicator: results from the PsoReal study.

Authors:  Marc A Radtke; Anna K Langenbruch; Ines Schäfer; Katharina Herberger; Kristian Reich; Matthias Augustin
Journal:  Patient Relat Outcome Meas       Date:  2010-12-22

Review 8.  The German National Program on Psoriasis Health Care 2005-2015: results and experiences.

Authors:  M Augustin; L Eissing; A Langenbruch; A Enk; T Luger; D Maaßen; U Mrowietz; K Reich; M Reusch; K Strömer; D Thaçi; R von Kiedrowski; M A Radtke
Journal:  Arch Dermatol Res       Date:  2016-04-05       Impact factor: 3.017

9.  Single-center, noninterventional clinical trial to assess the safety, efficacy, and tolerability of a dimeticone-based medical device in facilitating the removal of scales after topical application in patients with psoriasis corporis or psoriasis capitis.

Authors:  Ulrich R Hengge; Kristina Röschmann; Henning Candler
Journal:  Psoriasis (Auckl)       Date:  2017-06-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.